Here are the S-3 shelf registrations from Indaptus Therapeutics, Inc. (INDP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow INDP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INDP filings page.
Indaptus Therapeutics, Inc. is registering for resale up to 58,895,000 shares of Common Stock, all to be sold by existing holders. The company is not selling shares in this transaction and will receive no proceeds from these resales.
The registered shares comprise 20,000,000 shares sold in a June 17, 2026 private placement for $12.0 million and 38,895,000 shares issued upon conversion of 259,300 Series AAA Preferred originally sold to David Lazar and later transferred under a March 2026 secondary sale agreement. As of this prospectus, these 58,895,000 shares equal 44.2% of the 133,242,324 shares outstanding, creating a sizable potential resale overhang.
Indaptus, a clinical-stage immunotherapy company, has halted enrollment in all Decoy20 trials, has no active clinical programs, and is evaluating strategic alternatives, including transactions or new research initiatives. Recent financing history includes multiple 2024–2026 equity rounds, a now-terminated $20.0 million equity line, a 1-for-28 reverse stock split, and a December 2025 preferred investment that led to a March 2026 change of control. The most recent audit report includes a going-concern explanatory paragraph.
Indaptus Therapeutics, Inc. is registering for resale up to 18,864,000 shares of Common Stock by selling stockholders.
The prospectus states the Company will receive no proceeds from these resales and that the shares were issued principally upon conversion of preferred stock from the December 2025 financing and the March 2026 secondary transfer. The Company reports its last reported Nasdaq closing price was $3.775 per share as of June 22, 2026. The filing discloses that clinical development of Decoy20 has been paused: there are currently no participants in ongoing Decoy20 studies and the Company has substantially reduced Decoy20 development activities pending additional financing or strategic alternatives. The Company completed a June 17, 2026 private placement of 20,000,000 shares at $0.60 per share for gross proceeds of $12,000,000 and is required to file a resale registration covering those shares.